Initial anti-tumor activity data from ABILITY’s fifth and sixth dose escalation cohorts in calendar Q3 2023. Commencement of the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q3 2023. Clinical update from the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q4 2023. Commencement of the MDNA11 plus pembrolizumab combination arm of the ABILITY study in calendar Q4 2023.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
- Medicenna Therapeutics to present as NBTS Research Roundtable
- Medicenna Presents at National Brain Tumor Society’s Research Round Table
- Medicenna Therapeutics extends period to exercise certain warrants
- Oppenheimer waiting for further clinical updates on Medicenna Therapeutics